

# Marco Bono

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1038164/publications.pdf>

Version: 2024-02-01

14  
papers

326  
citations

840585

11  
h-index

1125617

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

411  
citing authors

#	ARTICLE	IF	CITATIONS
1	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103597.	2.0	19
2	BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103626.	2.0	6
3	Heart toxicity effects (HTE) of anthracyclines-containing regimens (ACRs) in patients with breast cancer (BC) carrying mutational signature of homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 10519-10519.	0.8	0
4	Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110497.	1.4	3
5	Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. <i>Journal of Molecular Pathology</i> , 2021, 2, 173-196.	0.5	14
6	Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. <i>Frontiers in Oncology</i> , 2021, 11, 682445.	1.3	14
7	A <i>Lymphocyte MicroRNA Signature</i> as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. <i>Cancers</i> , 2020, 12, 3396.	1.7	41
8	Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?. <i>Oncology Research and Treatment</i> , 2020, 43, 526-530.	0.8	16
9	Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. <i>Cancers</i> , 2020, 12, 2415.	1.7	40
10	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily) – Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes. <i>Cancers</i> , 2020, 12, 1158.	1.7	30
11	Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2020, 12, 534.	1.7	15
12	CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020008.	0.5	14
13	<i>BRCA1/2</i> pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097532.	1.4	34
14	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Advances in Therapy</i> , 2019, 36, 2600-2617.	1.3	80